Six updates in ovarian cancer (September is Ovarian Cancer Awareness Month)

medical news September 9, 2016

• READ/SUBMIT COMMENTS
• EMAIL

HemOnc Today presents six updates in gynecological cancer treatment and surveillance methods.

• The FDA granted priority review to rucaparib (Clovis Oncology) for the treatment of advanced ovarian cancer in patients with germline or somatic BRCA–mutated tumors. Read more.
• The use of power morcellation among women undergoing minimally invasive hysterectomy significantly decreased in the wake of an FDA recommendation against its use; however, the use of abdominal hysterectomy increased during this period. Read more.
• The FDA granted orphan drug designation to ZW25 and ZW33 for the treatment of ovarian cancer, according to the agents’ manufacturer. Read more.
• Neoadjuvant chemotherapy is the optimal first-line treatment for certain women with newly diagnosed advanced ovarian cancer, according to a joint clinical practice guideline from ASCO and the Society of Gynecologic Oncology. Read more.
• Cancer antigen 125 tests and CT scans are routinely used for surveillance of patients with ovarian cancer despite a lack of proven benefit, according to results of a prospective cohort study. Read more.
• The FDA issued a warning to alert patients and physicians that screening tests for ovarian cancer have been found unreliable and could lead to false diagnoses. Read more.